Glycomet SR: Advanced Sustained-Release Metformin for Optimal Glycemic Control
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.24 | $43.28 (0%) | 🛒 Add to cart |
| 270 | $0.21 | $64.92 $57.37 (12%) | 🛒 Add to cart |
| 360 | $0.20
Best per pill | $86.56 $71.46 (17%) | 🛒 Add to cart |
Similar products
Glycomet SR is a next-generation, sustained-release formulation of metformin hydrochloride, specifically engineered to provide consistent and prolonged glycemic management in patients with type 2 diabetes. By utilizing a sophisticated drug delivery system, it ensures a steady release of the active ingredient, minimizing peak-trough fluctuations and enhancing patient adherence through once-daily dosing. This medication works primarily by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues, making it a cornerstone therapy in diabetes management. Clinicians favor Glycomet SR for its balanced efficacy and tolerability profile, supporting long-term metabolic health.
Features
- Contains metformin hydrochloride in sustained-release tablets
- Available in strengths of 500 mg and 1000 mg
- Designed for once-daily oral administration
- Utilizes a hydrophilic matrix system for gradual drug release
- Bioequivalent to immediate-release metformin with reduced dosing frequency
- Manufactured under strict pharmaceutical quality standards
Benefits
- Provides 24-hour glycemic control with a single daily dose, enhancing convenience and compliance
- Reduces fasting and postprandial blood glucose levels effectively
- Lowers HbA1c significantly, decreasing the risk of diabetes-related complications
- Minimizes gastrointestinal side effects commonly associated with immediate-release metformin
- Supports weight neutrality or modest weight loss in many patients
- Improves lipid profiles by reducing triglycerides and LDL cholesterol
Common use
Glycomet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It may be used as monotherapy or in combination with other oral antihyperglycemic agents or insulin when glycemic targets are not achieved with lifestyle modifications alone. It is particularly suitable for patients who experience gastrointestinal intolerance with immediate-release metformin formulations.
Dosage and direction
The usual starting dose of Glycomet SR is 500 mg once daily with the evening meal. Dosage may be increased gradually in increments of 500 mg weekly, based on glycemic response and tolerability, up to a maximum recommended dose of 2000 mg once daily. Tablets should be swallowed whole with a glass of water; they must not be crushed, chewed, or split. Administration with meals is advised to further reduce potential gastrointestinal discomfort.
Precautions
- Renal function should be assessed before initiation and periodically thereafter; use is not recommended if eGFR is below 30 mL/min/1.73m².
- Avoid use in conditions predisposing to renal impairment, dehydration, or hypoxia.
- Temporarily discontinue prior to iodinated contrast imaging procedures and any surgical procedures.
- Monitor vitamin B12 levels annually or as clinically indicated during long-term therapy.
- Use with caution in elderly patients, hepatically impaired individuals, and those consuming alcohol.
Contraindications
- Hypersensitivity to metformin or any excipients in the formulation.
- Severe renal impairment (eGFR <30 mL/min/1.73m²) or renal disease.
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
- Acute conditions with the potential to alter renal function, such as dehydration, severe infection, or shock.
Possible side effect
Common side effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal discomfort, and anorexia, which are often transient and dose-related. Rare but serious adverse effects may include lactic acidosis (symptoms include malaise, myalgia, respiratory distress, somnolence), vitamin B12 deficiency with prolonged use, and hypoglycemia when used with other antidiabetic agents.
Drug interaction
- Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin) may interact by competing for renal tubular transport systems.
- Alcohol potentiates the effect of metformin on lactate metabolism and increases the risk of lactic acidosis.
- Glucocorticoids, diuretics, sympathomimetics, and phenothiazines may lead to loss of glycemic control.
- Hypoglycemic agents, including insulin and sulfonylureas, may enhance the risk of hypoglycemia.
Missed dose
If a dose of Glycomet SR is missed, it should be taken as soon as remembered on the same day. If it is almost time for the next scheduled dose, skip the missed dose and resume the usual dosing schedule. Do not take a double dose to make up for a missed one.
Overdose
Overdose of Glycomet SR may lead to lactic acidosis, a medical emergency characterized by acid-base imbalance, electrolyte disturbances, and hypothermia. Hypoglycemia has not been commonly reported with metformin overdose alone but may occur with concomitant use of other antidiabetic drugs. There is no specific antidote; management includes supportive measures, hemodialysis (which removes metformin), and correction of acidosis.
Storage
Store Glycomet SR tablets below 30°C, in a dry place, protected from light and moisture. Keep out of reach of children. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations based on individual health status and concurrent medications. Dosage adjustments and therapy decisions must be made under clinical supervision.
Reviews
Glycomet SR is highly regarded in clinical practice for its efficacy in maintaining stable blood glucose levels with improved gastrointestinal tolerability. Many healthcare providers note enhanced patient compliance due to the once-daily regimen. Some users report minimal side effects after the initial adjustment period, while long-term users appreciate the consistent metabolic benefits. Critical feedback occasionally highlights the need for careful dose titration in sensitive patients. Overall, it remains a trusted option in type 2 diabetes management protocols.